Sylvia Mcbrinn

Sylvia Mcbrinn

Director/Board Member chez BIOATLA, INC.

Fortune : 52 030 $ au 31/03/2024

71 ans
Health Technology
Consumer Services
Technology Services

Profil

Propel Bio Partners Senior Advisor Sylvia McBrinn is also a strategic Board Director, CEO, and commercialization expert with 30+ years of leadership experience in the biopharmaceutical industry.
With a strong commercial background in US and global markets, she has led successful launches of specialty to blockbuster products and grown market share for companies including Pfizer and Vernalis.
She provides biopharmaceutical companies critical insights from a career of executive governance, operational, and commercial success across a wide range of therapeutic areas including neurology, inflammation and rheumatology, pain, infectious disease/microbiome, and urology.
Currently, she serves and advises BioAtla (Nasdaq: BCAB) as Board Director, Compensation Committee Chair, and Audit Committee member, and as a Board Director of Ilya Pharma (private).
Until recently, she led as Board Director/founding CEO of early-stage biotech company Axerion Therapeutics (now ReNetX Bio), and also built and led the US subsidiary of a British biotech, Vernalis, with full P&L oversight.
Earlier, she was an EVP and GM of Andrx with full P&L responsibility, overseeing branded products with 400 employees across key business functions.
Throughout her career and board roles, she has earned a reputation of a strategic thinker with the ability to connect the dots and ask insightful questions between business direction, portfolio strategy, R&D, marketing, and commercialization.
As Global VP of Marketing at Pfizer, Ms. McBrinn led the launch and commercialization of the blockbuster product Bextra—the #1 Product launch in the US that year—achieving $1B in sales in the first 12 months and exceeding forecast by 35%.
Additionally, she built the #1 Parkinson’s disease product franchise globally, exceeding forecast by 40%.
At Vernalis, she in-licensed and relaunched Apokyn, an injectable Parkinson’s product that increased sales 42% YOY.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
26/12/2023 15 125 ( 0,03% ) 52 030 $ 31/03/2024

Postes actifs de Sylvia Mcbrinn

SociétésPosteDébut
BIOATLA, INC. Director/Board Member 15/06/2021
Corporate Officer/Principal -
Consultant / Advisor 01/03/2022
Tous les postes actifs de Sylvia Mcbrinn

Anciens postes connus de Sylvia Mcbrinn

SociétésPosteFin
Director/Board Member 01/06/2023
Founder 01/01/2012
Vernalis Pharmaceuticals, Inc. Corporate Officer/Principal 01/12/2008
Corporate Officer/Principal 01/01/2004
Pharmacia & Upjohn, Inc. Corporate Officer/Principal -
Voir l'expérience en détail de Sylvia Mcbrinn

Formation de Sylvia Mcbrinn

DeSales University Undergraduate Degree
Widener University Masters Business Admin

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Sylvia Mcbrinn

Relations

50

Relations au 1er degré

12

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées1
BIOATLA, INC.

Health Technology

Entreprise privées9
Pharmacia & Upjohn, Inc.

Health Technology

Health Technology

Health Technology

Health Technology

Technology Services

Health Technology

Vernalis Pharmaceuticals, Inc.

Health Technology

Finance

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Sylvia Mcbrinn